Open AccessThe comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor re
Author(s) -
V.V. Ryazhenov
Publication year - 2017
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/1815-1434_19.1.54-57
Subject(s) - afatinib , gefitinib , medicine , lung cancer , tyrosine kinase inhibitor , tyrosine kinase , oncology , pharmacology , cancer research , cancer , receptor , epidermal growth factor receptor